Carol Gallagher, Pharm.D., Chairperson
Partner, New Enterprise Associates, Inc.
An industry veteran with more than 25 years of experience in commercial, drug development and business development roles at large and small biopharmaceutical companies, Dr. Gallagher is a partner with New Enterprise Associates, Inc. (NEA). In addition to her role at NEA, Dr. Gallagher is the chairman of Atara Biotherapeutics and AnaptysBio. She previously served as the chairman of eFFECTOR Therapeutics, a director at Aragon Pharmaceuticals (acquired by Johnson & Johnson in 2013), and a venture partner with Frazier Healthcare. Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals, where she raised $80 million in venture financing and advanced the company's lead molecule, CAL-101, into full development, securing a successful exit with the $600 million acquisition by Gilead Sciences in April 2011. Dr. Gallagher began her career in sales and marketing at Eli Lilly in 1989 and also held various commercial and development roles at Amgen, Agouron Pharmaceuticals, Pfizer, CancerVax and Anadys. Notable during her career was her role as the Rituxan Development Team Leader at Idec Pharmaceuticals and after the merger, Biogen Idec.
Dr. Gallagher attended Vanderbilt University and holds B.S. and Pharm.D. degrees from the College of Pharmacy at the University of Kentucky.
Mary Lynne Hedley, Ph.D.
President, Chief Operating Officer, TESARO, Inc.
Dr. Mary Lynne Hedley has served as President and as a member of the board of directors of TESARO, Inc. since co-founding the company in March 2010. Prior to TESARO, Dr. Hedley served as Executive Vice President of Operations and Chief Scientific Officer of Abraxis BioScience, a biotechnology company. Dr. Hedley previously served as Executive Vice President of Eisai Corporation of North America following the company's acquisition of MGI Pharma in January 2008. Prior to its acquisition by Eisai, Dr. Hedley served in various positions at MGI Pharma, including Executive Vice President and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and served as the President and Chief Executive Officer of Zycos, a biotechnology company which was acquired by MGI Pharma in 2004.
Dr. Hedley earned her Ph.D. in immunology from the University of Texas, Southwestern Medical Center and her B.S. in microbiology from Purdue University. Her postdoctoral training included two consecutive postdoctoral fellowships at Harvard University. She currently serves on the Board of Directors of Youville Place, an assisted living facility, and previously served on the Board of Directors of Receptos until its acquisition by Celgene.
Mr. James Hindman has over 30 years of global and strategic senior financial experience in the pharmaceutical, biologics, and medical device industries. He enjoyed a long and esteemed career with Allergan, Inc., starting with the company as Manager of Accounting in 1984 and most recently serving as Executive Vice President of Finance and Business Development and Chief Financial Officer. Under his leadership, Allergan achieved its most robust financial performance in the company’s 64-year history. Mr. Hindman was instrumental in facilitating the largest restructuring and rewiring of Allergan, creating $20B in shareholder value that ultimately led to Actavis’ acquisition of Allergan in 2015 and the creation of one of the top ten global pharmaceutical firms. During his 30-year tenure at Allergan, Mr. Hindman held various senior leadership positions including Executive Vice President of Finance and Business Development and Chief Financial Officer, and Senior Vice President, Finance and Controller, and was responsible for strategic and financial functions including treasury, investor relations, risk, controller, financial reporting, SEC compliance, audits, acquisitions and divestitures, and strategic planning. Additionally, he served as President of the Allergan Foundation from 2009-2015.
Mr. Hindman earned his MBA from Pepperdine University and a B.S. in accounting from Loyola Marymount University. He currently serves as Director of NeuroSigma, Inc. and is a member of the Loyola Marymount University Board of Trustees.
Carole Nuechterlein, J.D.
Head, Roche Venture Fund
Ms. Carole Nuechterlein joined F. Hoffmann-La Roche Ltd. in 2001 and currently serves as Head of the Roche Venture Fund. Previously, Ms. Nuechterlein served as General Counsel for SangStat, Inc. She began her career in the mergers and acquisitions group at Skadden Arps Slate Meagher & Flom.
Ms. Nuechterlein earned her B.A. from Valparaiso University and J.D. from the University of Michigan. She currently serves on the board of directors for AveXis, CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Mission Therapeutics, Second Genome, and Tioma Therapeutics and as an observer at Allakos and MacuLogix. Her previous investment and board experience includes Alios BioPharma, Ambit Biosciences, Envoy Therapeutics and Pharmasset.
Julia C. Owens, Ph.D.
President and Chief Executive Officer, Millendo Therapeutics, Inc.
Dr. Julia C. Owens has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that led to Lycera's major research partnership with Merck & Co. She also acquired a new platform discovery program for the company and negotiated its partnership with the University of Michigan, moving the company to the North Campus Research Complex. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. There, she established several key partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) in business development for five years, where she led partnering for the oncology and immunology areas, as well as chaired the company's technology acquisition efforts. Dr. Owens began her business career at the University of California, San Francisco Office of Technology Management.
Dr. Owens holds a Ph.D. in biochemistry from the University of California, San Francisco and a B.S. in chemistry and B.A. in molecular and cellular biology from the University of California, Berkeley.
Jamie Topper, M.D., Ph.D.
General Partner, Frazier Healthcare Partners
Dr. Jamie Topper is a Managing General Partner of Frazier Healthcare Partners’ Life Sciences team. Throughout his 11 years as a General Partner, Jamie has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier’s successful life sciences investments, including Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), Cotherix (sold to Actelion), and Threshold (NASDAQ: THLD). In addition to Millendo, he currently represents Frazier on the boards of Alcresta, Allena Pharmaceuticals, Anaptys Biotech, Aptinyx, Entasis Therapeutics, Merganser Biotech, and ProNai Therapeutics (NASDAQ: DNAI).
Prior to joining Frazier, Dr. Topper served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR.
Dr. Topper received his M.D. and Ph.D. in biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He completed his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women's Hospital in Boston and is board certified in both disciplines. He has authored over 50 publications and was the recipient of a Howard Hughes Scholars Award while on the faculty at Stanford University. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013 was recognized by Forbes as one of the top 10 healthcare investors.
Randall Whitcomb, M.D.
Dr. Randy Whitcomb has over 35 years of experience as an endocrinologist, chief medical officer, and drug development executive. He is a Senior Advisor to Frazier Healthcare Partners' Life Sciences team and is closely involved with the sourcing and evaluation of new opportunities. He has been involved with a number of portfolio companies to assist with clinical trial design and execution, regulatory strategy, and other development-related activities.
Previously, Dr. Whitcomb was a co-founder and Chief Medical Officer of QuatRx Pharmaceuticals, a pharmaceutical company focusing on compounds in the endocrine and metabolic therapeutic areas. Earlier he served in various management positions at Parke-Davis, the pharmaceutical division of Warner-Lambert, including VP for Clinical Research and Drug Development. After Pfizer acquired Warner-Lambert, Dr. Whitcomb was VP of Global Project Management for Pfizer. Throughout his time in the pharmaceutical industry, he has been involved in the development and approval of several drugs including: Lipitor, Rezulin, FemHRT, Estrostep, and Osphena. Prior to his tenure at Parke-Davis, Dr. Whitcomb was on the faculty of the Harvard Medical School and an attending physician at Massachusetts General Hospital. He previously served on the boards of Insmed, Inc. and Marcadia Biotech, Inc.
Dr. Whitcomb received his M.D. from the University of Kansas, where he did clinical training in internal medicine and endocrinology followed by a research fellowship at N.I.H. He earned a B.A. in Biology and Chemistry from Tabor College. Randy has authored multiple scientific publications and is a member of numerous scientific and clinical organizations.
Thierry Abribat D.V.M., Ph.D.
Founder, Alizé Pharma
Since 2007, Dr. Thierry Abribat has served as the founder and manager of the Alizé Pharma organization, a group of biotech companies operating under an asset-based model. Over the last 10 years, he has founded and managed 3 companies, one of which, Alizé Pharma II, was divested to Jazz Pharmaceuticals (Nasdaq: JAZZ) and, another, Alizé Pharma, was acquired by Millendo Therapeutics. Through TAB Consulting, his holding company, he is also the founder and President of Alizé Pharma III SAS, a biotech company developing drugs for rare diseases and bone diseases, and an advisor to Millendo Therapeutics.
Dr. Abribat began his career as scientist at Sanofi-Recherche, then at University of Montreal and as a consultant to the biopharmaceutical industry. He then held several executive positions with increasing responsibilities in drug development, business development and management at Theratechnologies (TSX: TH) and at OPi, Pharmaceuticals for Rare Diseases, until OPi’s acquisition by EUSA Pharma Inc.
Dr. Abribat holds a Doctor of Veterinary Medicine and a Ph.D. from the National Polytechnic Institute of Toulouse.